Navigation Links
Novavax Prices Public Offering of Common Stock
Date:11/20/2009

age biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from those expressed or implied by such forward-looking statements. Such factors include, among other things, the following: our ability to satisfy all required closing conditions of the offering; our ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity or debt financing or otherwise; general business conditions; competition; business abilities and judgment of personnel; and other factors referenced herein. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.

SOURCE Novavax, Inc.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Novavax CEO to Present at BIO CEO & Investor Conference
2. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
3. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
4. Novavax CEO to Present at the World Vaccine Congress 2008
5. Novavax Opens Its First U.S. Vaccine Plant
6. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
7. Novavax Reports First Quarter 2008 Financial Results
8. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
9. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
10. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
11. Novavax to Join Russell 3000 Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Pittcon Organizing Committee is pleased to ... Tech , an e-Journal and producer of Food ... second year for the co-location of Food Labs Conference to ... that the registration fee to attend the two-day Food Lab ...
(Date:1/15/2014)... , Jan. 15, 2014 ­ RedBrick Health ... behavior change technology, today announces that EmblemHealth , ... and wellness company, is now providing the RedBrick Compass ... coaching program, to all of its members. EmblemHealth is ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains ... these latent viruses is the Epstein Barr Virus (EBV), and ... (RA) is a chronic inflammatory disease that destroys the body’s ... RA patients have high concentrations of EBV DNA in their ...
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, Limited ... agreement with R-Pharm, a leading Russian pharmaceutical company, to ... Russian Federation , Turkey ... States (CIS). Nemonoxacin is a novel antibiotic for the treatment ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... Cell Therapeutics, Inc. ("CTI" or the "Company") (NASDAQ and MTA: ... first quarter of 2012. First Quarter ... expenses were $18.1 million compared to $20.1 million for the ... decreased 66% to $17.4 million ($0.09 per share) for the ...
... Mich., April 19, 2012  Researchers at Lund University in Sweden ... These cells can proliferate and form several different cell types ... hope to take advantage of the finding to develop methods ... Analyzing brain tissue from biopsies, the researchers for ...
... NAPERVILLE, Ill., April 19, 2012  Phigenics LLC, an innovative ... a research paper that demonstrates up to 33% false-positive ... conventional sampling methods. A false-positive result means the test ... system at detectable levels when in fact it was ...
Cached Biology Technology:Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones 2Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones 3Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones 4Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones 5New Stem Cell Found in the Brain 2New Stem Cell Found in the Brain 3Phigenics Research Challenges Accuracy Of Conventional Legionella Testing Protocol 2Phigenics Research Challenges Accuracy Of Conventional Legionella Testing Protocol 3
(Date:4/17/2014)... the immune system may fight cancers and viral infections. ... to treat illness. , The research, in mice, suggests ... police" specialized squads of defenders that patrol only ... city, the body. , Scientists at Washington University School ... liver, skin and uterus each has dedicated immune cells, ...
(Date:4/16/2014)... legal, artisanal green sea turtle fishery has uncovered a ... in what may have become an unsustainable take, according ... University of Florida. , During the research period, conservation ... killed between 1991 and 2011, with catch rates peaking ...
(Date:4/16/2014)... you cannot lift your upper eyelid. You walk through life with ... they are rolled down in the eye socket. Obviously, such a ... their head. In order to correct this condition, one would need ... the April 16 print issue of the journal Neuron , ...
Breaking Biology News(10 mins):Some immune cells defend only 1 organ 2Declining catch rates in Caribbean green turtle fishery may be result of overfishing 2Declining catch rates in Caribbean green turtle fishery may be result of overfishing 3Researchers track down cause of eye mobility disorder 2
... A deep ocean current with a volume equivalent to 40 ... near the Kerguelen plateau, in the Indian Ocean sector of ... paper published today in Nature Geoscience , the researchers ... surface as an important pathway in a global network ...
... National Oceanography Centre in Southampton, have today set sail from ... Ocean affected by ash from the Icelandic volcano eruption to ... of the ocean the productivity of microscopic plants, called phytoplankton, ... sequester carbon dioxide from the atmosphere, is limited by the ...
... Spanish . , Two new compact oakleaf ... by Agricultural Research Service (ARS) scientists. "Ruby Slippers" ... geneticist Sandy Reed with the U.S. National Arboretum,s Floral ... The arboretum is operated by ARS, the principal intramural ...
Cached Biology News:Massive Southern Ocean current discovered 2Scientists to measure impact of volcanic ash on ocean biology 2New hydrangea cultivars for landscape gardens 2
[14C]Polyethylene glycol 4000, 9.25 MBq, 250 uCi. Aqueous solution containing 3% ethanol, sterilized. 370-740 MBq/g, 10-20 mCi/g.1.85 MBq/ml, 50 uCi/ml. Category: Radiochemicals &Radiation Safety, ...
An instrument that delivers an accurate and uniform amount of light energy to cells to photoactivate csiRNA products....
... kit for all types of yeast two-hybrid studies, including ... Choice of two bait vectors for ... Triple reporter strain ... Complete set of controls: pLexA-p53, ...
interferon-related developmental regulator 2...
Biology Products: